A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment

Current treatments for inflammatory bowel disease (IBD) treatment consist of anti-inflammatory products. In this study, we sought to induce the physiological secretion of glucagon-like peptide 2, a peptide with intestinal growth-promoting activity, via nanoparticles while simultaneously providing wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Marotti, Valentina, Xu, Yining, Bohns Michalowski, Cécilia, Zhang, Wunan, Domingues, Inês, Ameraoui, Hafsa, Moreels, Tom G., Baatsen, Pieter, Van Hul, Matthias, Muccioli, Giulio G., Cani, Patrice D., Alhouayek, Mireille, Malfanti, Alessio, Beloqui, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582360/
https://www.ncbi.nlm.nih.gov/pubmed/37859689
http://dx.doi.org/10.1016/j.bioactmat.2023.09.014
Descripción
Sumario:Current treatments for inflammatory bowel disease (IBD) treatment consist of anti-inflammatory products. In this study, we sought to induce the physiological secretion of glucagon-like peptide 2, a peptide with intestinal growth-promoting activity, via nanoparticles while simultaneously providing with immunomodulation by tailoring the nanoparticle surface. To this end, we developed hybrid lipid hyaluronate-KPV conjugated nanoparticles loaded with teduglutide for combination therapy in IBD. The nanocarriers induced (or did not induce) immunosuppression depending on the presence (or absence) of a hyaluronan-KPV functionalization. This strategy holds promise as a nanoparticle platform for combined mucosal healing and immunomodulation in IBD treatment.

Ejemplares similares